干扰素联合白介素-2治疗宫颈高危型HPV感染的临床研究

Interferon Combination Interleukin-2 Txeatment Cervical High-Risk Type HPV Infection of Clinical Research

目的探讨干扰素联合白介素-2治疗宫颈高危型人乳头瘤病毒（hr—HPV）感染的临床疗效。方法将34例宫颈高危型HPV感染患者随机分为3组，治疗A组12例予干扰素联合白介素-2治疗，治疗B组11例予干扰素治疗，对照组11例不予治疗；观察治疗后患者的HPV转阴率、不良反应。结果治疗A组、治疗B组、对照组hr-HPV的转阴率分剐为91．7％、72．7％、9．1％，治疗A组、治疗B组与对照组比较，差异有显著性（P〈0．01）；治疗A组转阴率高于治疗B组（P〈0.05）。治疗A组、B组的不良反应发生率为25％、27．3％。结论干扰素联合白介素-2治疗宫颈高危型HPV感染疗效较显著。不良反应少，远期疗效和不良反应仍有待进一步研究。

Objective： To investigate clinical efficacy of interferon combined interleukin-2 in treatment of cervical high-risk human papilloma virus （hr-HPV） infection. Methods： 34 cases cervical high-risk HPV irffection were randomly divided into three groups, 12 patients of treatment A group treated for interferon combination with interleukin-2, 11 patients of treatment B group took interferon therapy, 11 patients of control group Untreated. After treatment, observed HPV-negative rate, adverse reactions of patients. Results： Hr-HPV negative rates of treatment A Group, treatment B group and the control group were 91.7%, 72.7%, 9.1%, the treatment group A, group B compared with the control group, the difference was significant （P〈 0.01 ）; the negative rate of treatment group A higher than treatment of group B （P〈0.05）. Adverse events of treatment group A and B group of were 25%, 27.3%. Conclusion： Interferon combined interleukin-2 treatment of cervical high-risk HPV infection had more significant effects, adverse reactions, but long-term efficacy and adverse effects remain to be further studied.